argenx opens Phase 1 bioequivalence trial comparing efgartigimod autoinjector to prefilled syringeAug 24Trial updateargenxefgartigimod
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositisAug 17Clinical readoutargenxefgartigimod
argenx posts ADAPT SERON Phase 3 results; registers new Phase 2 in Sjögren's neuropathyAug 12Weekly roundup, 2 itemsargenxefgartigimod
TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidanceAug 3Quarterly updateTG Therapeutics, Inc.ublituximab
TG Therapeutics registers two Phase 2 ublituximab trials, in schizophrenia and myasthenia gravisJul 2Weekly roundup, 2 itemsTG Therapeutics, Inc.ublituximab
Sign inSign in